Identification and characterization of the first fragment hits for SETDB1 Tudor domain.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 24 05 2019
revised: 03 07 2019
accepted: 10 07 2019
pubmed: 23 7 2019
medline: 23 9 2020
entrez: 23 7 2019
Statut: ppublish

Résumé

SET domain bifurcated protein 1 (SETDB1) is a human histone-lysine methyltransferase which is amplified in human cancers and was shown to be crucial in the growth of non-small and small cell lung carcinoma. In addition to its catalytic domain, SETDB1 harbors a unique tandem tudor domain which recognizes histone sequences containing both methylated and acetylated lysines, and likely contributes to its localization on chromatin. Using X-ray crystallography and NMR spectroscopy fragment screening approaches, we have identified the first small molecule fragment hits that bind to histone peptide binding groove of the Tandem Tudor Domain (TTD) of SETDB1. Herein, we describe the binding modes of these fragments and analogues and the biophysical characterization of key compounds. These confirmed small molecule fragments will inform the development of potent antagonists of SETDB1 interaction with histones.

Identifiants

pubmed: 31327677
pii: S0968-0896(19)30870-3
doi: 10.1016/j.bmc.2019.07.020
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
Histones 0
Small Molecule Libraries 0
Histone-Lysine N-Methyltransferase EC 2.1.1.43
SETDB1 protein, human EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3866-3878

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Pavel Mader (P)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Rodrigo Mendoza-Sanchez (R)

Department of Chemistry, University of Toronto, Toronto, Canada.

Aman Iqbal (A)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Aiping Dong (A)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Elena Dobrovetsky (E)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Victoria B Corless (VB)

Department of Chemistry, University of Toronto, Toronto, Canada.

Sean K Liew (SK)

Department of Chemistry, University of Toronto, Toronto, Canada.

Scott R Houliston (SR)

Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Canada.

Renato Ferreira De Freitas (RF)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

David Smil (D)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Carlo C Dela Sena (CCD)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Steven Kennedy (S)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Diego B Diaz (DB)

Department of Chemistry, University of Toronto, Toronto, Canada.

Hong Wu (H)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Ludmila Dombrovski (L)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Abdellah Allali-Hassani (A)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Jinrong Min (J)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Matthieu Schapira (M)

Structural Genomics Consortium, University of Toronto, Toronto, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Masoud Vedadi (M)

Structural Genomics Consortium, University of Toronto, Toronto, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Peter J Brown (PJ)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Vijayaratnam Santhakumar (V)

Structural Genomics Consortium, University of Toronto, Toronto, Canada.

Andrei K Yudin (AK)

Department of Chemistry, University of Toronto, Toronto, Canada. Electronic address: andrei.yudin@utoronto.ca.

Cheryl H Arrowsmith (CH)

Structural Genomics Consortium, University of Toronto, Toronto, Canada; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Canada. Electronic address: Cheryl.Arrowsmith@uhnresearch.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH